Reiterated 2023 guidance is: $3.25-3.45 of non-GAAP EPS; $67-71M of revenue including $21.5B for COVID products ($13.5B Comirnaty, $8B Paxlovid); and organic sales growth excluding COVID products of 7-9%.
1Q23 COVID sales were $7.1B ($2.9B Comirnaty, $4.1B Paxlovid).
News 
Market Data 
Discover 
